



Patent
266/171

TECH CENTER 1600/2900

JUN 04 2002

RECEIVED

#12

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:) Group Art Unit: 1642
MIROCHNITCHENKO, Oleg et al.) Examiner: not yet assigned
Serial No.: 09/960,631)
Filed: September 20, 2001)
For: SOLUBLE ISCHEMIA ACTIVATED)
PROTEIN)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Information Disclosure Statement (“IDS”) are brought to the attention of the Office. The items are listed on the attached form PTO-1449 and copies are enclosed for the convenience of the Examiner.

The items identified in this IDS may or may not be “material” pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as “prior art” under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

LA-236725.1

CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

May 22, 2002

Date of Deposit

Rachel Marquez

Name of Person Mailing Paper

Signature of Person Mailing Paper

INFORMATION DISCLOSURE STATEMENT FILING PROVISION:

This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution application filed under § 1.53(d); or (2) within three months of entry of the national stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.

However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR § 1.17(p) or any fees required by this filing to Lyon & Lyon's Deposit Account No. **12-2475**.

Respectfully submitted,
LYON & LYON LLP

Dated: 5/22/02

By:

Sandra S. Fujiyama
Sandra S. Fujiyama
Reg. No. 46,713



22249

PATENT TRADEMARK OFFICE

LYON & LYON LLP
633 W. Fifth Street, Suite 4700
Los Angeles, CA 90071
Phone: (213) 489-1600
Fax: (213) 955-0440

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				ATTY. Docket No. 266/171	SERIAL NO. 09/960,631
				APPLICANT: MIROCHNITCHENKO, Oleg et al.	
				FILING DATE: September 20, 2001	GROUP: 1642

RECEIVED
JUN 04 2002
TECH CENTER 1600/2800

MAY 28 2002
PARENT & EXAMINER
SEARCHED INDEXED
O P E R A T I O N S
EXAMINER
INITIAL JCS

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
AA	4,376,110	3/8/83	David et al.	436	513	8/4/80

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

AB	Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., April 1993
AC	Bousquet et al., "Eosinophilic Inflammation in Asthma," New Eng. J. Med., Vol. 323, No. 15, (1990) pp. 1033-1039
AD	Chiramonte et al., "ID-13 Is a Key Regulatory Cytokine for Th2 Cell-Mediated Pulmonary Granuloma Formation and IgE Responses Induced by Schistosoma mansoni Eggs," J. Immunol., Vol. 162, (1999) pp. 920-930
AE	Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer," Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., New York, NY (1985) pp. 77-96 (1985).
AF	Corry, "IL-13 in allergy: home at last," Curr. Opin. Immunol., Vol. 11, No. 6, (12/1999) pp. 610-614
AG	Creighton, "Proteins: Structure And Molecular Properties," 2nd Ed., W. H. Freeman and Company, New York (1993)
AH	Daniels et al., "A genome-wide search for quantitative trait loci underlying asthma," Nature, Vol. 383, (9/19/1996) pp. 247-250
AI	Davis et al., "Basic Methods In Molecular Biology," Elsevier Science Publishing Co., Inc., New York, New York, (1986)
AJ	de Vries, "The role of IL-13 and its receptor in allergy and inflammatory responses," J. Allergy Clin. Immunol., Vol. 102, No. 2 (8/1998) pp. 165-172
AK	Donaldson et al., "The Murine IL-13 Receptor α2: Molecular Cloning, Characterization, and Comparison with Murine IL-3 Receptor α1," J. Immunol., Vol. 161, (1998) pp. 2317-2324
AL	Emson et al., "Interleukin (IL)-4-independent Induction of Immunoglobulin (Ig)E, and Perturbation of T Cell Development in Transgenic Mice Expressing IL-13," J. Exp. Med., Vol. 188, No. 2, (7/20/1998) pp. 399-404
AM	Gavett et al., "Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice," Am. J. Physiol., Vol. 272, (1997) pp. L235-L261
AN	Grünig et al., "Requirement for IL-13 Independently of IL-4 in Experimental Asthma," Science, Vol. 282, (12/18/1998) pp. 2261-2263
AO	Hilton et al., "Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor," Proc. Natl. Acad. Sci. USA, Vol. 93, (1/1996) pp. 497-501
AP	Jensen, "The Interleukin 13 Receptor Complex," Stem Cells 2000, Vol. 18, (2000) pp. 61-62
AQ	Johnson, "Posttranslational Covalent Modifications of Proteins," Academic Press, Inc., New York (1983)

LA-236309.1

EXAMINER:	DATE CONSIDERED:
Not yet assigned	

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609;
Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. Docket No.
266/171SERIAL NO.
09/960,634APPLICANT:
MIROCHNITCHENKO, Oleg et al.FILING DATE:
September 20, 2001GROUP:
1642

MAY 28 2002

RECEIVED
TECH CENTER 1600/2800
JUN 04 2002

PATENT & TRADEMARK OFFICE	REF ID	CITATION
	AS	Kelly, "Intercellular Adhesion Molecule-1-deficient Mice Are Protected against Ischemic Renal Injury," J. Clin. Invest., Vol. 97, No. 4, (2/1996) pp. 1056-1063
	AT	Köhler et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," Nature, Vol. 256, (8/7/1975) pp. 495-497
	AU	Kozbor et al., "The production of monoclonal antibodies from human lymphocytes," Immunology Today, Vol. 4, No. 3, (1983) pp. 72-79
	AV	Murata et al., "Structure of IL-13 Receptor: Analysis of Subunit Composition in Cancer and Immune Cells," Biochem. and Biophys. Res. Commun., Vol. 238, (1997) pp. 90-94
	AW	Opal et al., "Anti-Inflammatory Cytokines," Impact of Basic Research on Tomorrow's Medicine, Chest, Vol. 117, No. 4, (4/2000) pp. 1162-1172
	AX	Rattan et al., "Protein Synthesis, Posttranslational Modifications, and Aging," Ann. NY Acad. Sci., Vol. 663, (1992) pp. 48-62
	AY	Sambrook et al., "Molecular Cloning: A Laboratory Manual," Third Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989)
	AZ	Seifter et al., "Analysis for Protein Modifications and Nonprotein Cofactors," Methods in Enzymology, Vol. 182, (1990) pp. 626-646
	BA	Taylor, "The Classification of Amino Acid Conservation," J. theor. Biol., Vol. 119, (1986) pp. 205-218
	BB	Wills-Karp et al., "Interleukin-13: Central Mediator of Allergic Asthma," Science, Vol. 282, (12/18/1998) pp. 2258-2260
	BC	Zurawski et al., "Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells," Immunol. Today, Vol. 15, No. 1 (1994) pp. 19-26

LA-236309.1

EXAMINER: Not yet assigned	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant	